2型糖尿病患者肺功能变化及其相关因素分析研究

目的探讨2型糖尿病患者肺功能变化及其相关因素。方法用肺功能指标测定入选74例2型糖尿病患者（糖尿病组）的肺功能并同时测定三酰甘油、胆固醇、C反应蛋白、同型半胱氨酸、脂蛋白a、空腹血糖、空腹胰岛素、糖化血红蛋白（HbA1 c）检查以及尿蛋白排泄率（AER）检测、眼底检查以及神经传导速度检查,计算胰岛素抵抗指数;74例无糖尿病患者为对照组完成9个月的观察,比较两组肺功能变化,并对糖尿病组肺功能变化的相关因素进行多因素线性回归分析。结果糖尿病组肺活量（VC）、1s用力呼气容积（FEV1）、肺总量（TLC）、最大自主通气量（MVV）、肺-氧化碳弥散量（DLCO）、肺单位体积-氧化碳弥散量（KCO）均明显低于对照组（P〈0.05）。对糖尿病组进行线性相关分析表明,VC、FEV1、TLC均与HbA1 c呈显著负相关（P〈0.01）,且VC与同型半胱氨酸呈显著负相关（P〈0.05）,MVV与微血管并发症积分呈显著相关性（P〈0.01）。DLCO、KCO均与HbA1 c、微血管并发症积分呈负相关（P〈0.05）,DLCO亦与胰岛素抵抗指数呈显著负相关（P〈0.05）,并对糖尿病患者肺功能指标与多种相关因素进行多因素线性回归分析。结论 2型糖尿病患者存在肺通气功能及弥散功能减退,肺脏可能是糖尿病慢性病变的靶器官之一,控制血糖、改善胰岛素抵抗、抗氧化应激治疗是其防治重点。     

2型糖尿病患者肺功能变化及相关风险因素分析

目的探讨T2DM患者肺功能变化及相关因素分析。方法对98例T2DM(T2DM组)患者和100名健康志愿者(NC组)进行肺功能检查,并对T2DM组肺功能变化的相关因素进行多因素线性回归分析。结果 T2DM组肺活量(VC)、用力肺活量(FVC)、一秒用力呼气流量(FEVl)、最大呼气峰流速(PEF)、最大自主通气量(MVV)、肺总量(TLC)、一秒率(FEV1/FVC)、肺一氧化碳弥散量(DL-CO)、肺单位体积一氧化碳弥散量(DLCO/VA)分别为(80.78±14.70)、(70.95±14.90)、(76.59±16.01)、(52.45±16.60)、(66.71±23.72)、(0.86±12.50)、(87.49±8.39)、(69.29±15.35)、(79.62±19.73),均低于NC组(P<0.05)。T2DM组DLCO与糖尿病病程(r=-0.45,P<0.05)、微血管病变积分(r=-0.37,P<0.05)、胰岛素抵抗指数(HOMA-IR)(r=-0.31,P<0.05)呈负相关。结论 T2DM组肺功能也存在损害,这种损害和糖尿病病程及糖尿病微血管慢性病变程度以及患者IR状态密切相关。     

2型糖尿病患者肺功能改变及其相关因素分析

测定87例2型糖尿病患者（DM组）和42例健康人（对照组）的肺功能，并对DM组肺功能变化进行多因素线性回归分析。结果DM组总肺活置（TLC）、用力肺活量（FVC）、1s用力呼气量（FEV1）、用力呼气流量（FEF25、FEF50、FEF75）、肺一氧化碳弥散量（DLCO）均明显低于对照组（P〈0．05或P〈0．01）；TLC、FVC、FEV1、FEF50、FEF75与空腹血糖（FPG）、餐后2h血糖、空腹胰岛紊（FINS）、餐后2h胰岛素、糖化血红蛋白、胰岛素敏感指数（ISI）、体重指数（BMI）及微血管并发症积分无明显相关性（P〉0．05），FEF25、DLCO与FPG、FINS、ISI及微血管并发症积分显著相关（P〈0．05或P〈0．01）。提示2型糖尿病患者存在以限制性为主的肺通气功能障碍和弥散功能障碍，FPG、FINS、ISI及微血管并发症等可能是影响其肺功能的主要因素。     

肝硬化与肺功能异常的关系

目的:了解肝硬化患者肺功能异常与肝病之间的关系.方法:选取2007-05/2008-03我院及中山大学附属第一医院住院肝硬化患者50例.肺功能检测患者第一秒用力呼气量(FEV1)、一秒率(FEV1/FVC),单次呼吸法检测肺一氧化碳弥散量(DLCO)、比弥散量(KCO,即单位肺泡的DLCO).将肝硬化患者分别按患者肝掌、蜘蛛痣、显性黄疸、白蛋白减低、脾亢、门静脉增宽等的异常与否分成阳性组(+)和阴性组(-),比较组间FEV1、FEV1/FVC、DLCO、KCO均值的差异.结果:约34%患者出现通气功能障碍,以限制性通气为主:有72%的患者出现弥散功能减退,为最主要的肺功能改变.Child-Pugh积分与KCO呈负相关(r=-0.351,P<0.05);白蛋白水平与FEV1、KCO呈正相关(r=0.334,0.336,均P<0.05);门静脉宽度与FEV1、DLCO呈负相关(r=-0.389,-0.417,均P<0.05);脾厚度与DLCO、KCO呈负相关(r=-0.644,-0.536,均P<0.01).血红蛋白浓度和脾脏厚度是DLCO的独立预测因子(P<0.05).结论:弥散障碍在肝硬化患者中发生率较高,门静脉高压的长期作用与之有密切关系.     

不同阶段2型糖尿病患者肺功能分析

目的通过对不同阶段2型糖尿病患者的肺功能进行分析,以明确糖尿病患者是否存在肺功能损害。方法对60例2型糖尿病患者(初发糖尿病患者30例,合并不同并发症患者30例)和60例健康志愿者分别进行肺功能检测,检测其用力肺活量(FVC)、1秒钟用力呼气容积(FEVI)、1秒率(FEVl/FVC)、肺一氧化碳弥散(DLCO)及单位肺泡一氧化碳弥散量(DLCO/VA)肺功能指标数据,采用SPSS17.0软件进行统计学处理,分析不同阶段2型糖尿病患者的肺功能变化。结果糖尿病组FVC、DLCO及DLCO/VA低于健康对照组,差异有统计学意义(P0.05);且有并发症组较无并发症组以上各项指标进一步下降,差异有统计学意义(P0.05)。结论糖尿病患者肺功能减退,且以弥散功能下降显著,且随疾病进展,糖尿病出现并发症的患者肺弥散功能更加减退,积极控制血糖,延缓并发症的产生,可进一步减缓肺功能的减退。     

糖尿病对慢性阻塞性肺疾病患者肺功能影响的相关性研究

目的观察糖尿病对于慢性阻塞性肺疾病(COPD)患者肺功能及血气分析情况的影响。方法回顾性分析2015年1月—2016年12月间在该院诊治的慢性阻塞性肺疾病(COPD)患者80例,根据有无合并糖尿病,分为试验组及对照组,通过肺功能检测及血气分析,测量VC、FVC、FEV1、FEV1/FVC、PEF、弥散量DLCO与比弥散量DLCO/PRED等肺功能指标,并进行组间比较,分析严重程度之间的差异。结果试验组肺功能指标显著低于对照组。试验组的疾病严重程度也高于对照组患者,差异有统计学意义(P0.05)。结论慢性阻塞性肺疾病(COPD)患者合并糖尿病时,其的肺功能受损情况更严重,COPD合并糖尿病时肺通气功能和弥散功能都可受损。     

利拉鲁肽对2型糖尿病肺功能影响

40例糖化血红蛋白〉9％的2型糖尿病患者随机分为胰岛素组和利拉鲁肽组（n=20）,22例为对照,采用肺功能仪测定肺通气功能指标和DLCO（一氧化碳肺弥散功能）。结果与对照组相比,2型糖尿病患者的肺通气功能指标（VC、FVC、FEVl、TLC、MVV）和DLCO明显下降（P〈0．05）。12周后胰岛素组肺通气功能指标轻度增加,但无统计学意义,而弥散功能指标DLCO明显增加（P〈0．05）。利拉鲁肽组肺通气功能指标及弥散功能指标均明显高于胰岛素组（P值均〈0．05）。结论2型糖尿病血糖控制不良患者肺功能明显降低,与胰岛素比较,利拉鲁肽可明显改善2型糖尿病患者肺功能。     

肺泡蛋白沉着症肺功能检查特点:附27例分析

目的 肺泡蛋白沉着症(PAP)在临床上极为罕见,其肺功能检查特点的报道也极少,本研究目的在于探讨肺功能检查在PAP诊断和治疗中的价值.方法 回顾性分析本院呼吸疾病研究所经肺组织病理(过碘酸雪夫反应阳性)确诊的27例PAP患者的临床资料.全部病例均给予肺通气和弥散功能测试,其中12例进行了肺容积测试.比较了10例行支气管肺泡灌洗(BAL)治疗的患者在灌洗前、后肺功能的改变情况.结果 27例患者入院后的基础通气肺功能情况:用力肺活量(FVC):(79.67±16.21)%;第1秒用力呼气容积(FEV1):(83.94±16.07)%,一秒率(FEV1/FVC):(89.20±5.50)%;最大呼气流量(PEF):(107.64±17.73)%;肺一氧化碳弥散量(DLCO):(49.27±21.83)%;DLCO与肺泡通气量比值(DLCO/VA):(69.92±20.11)%.肺总量(TLC):(80.60±19.56)%;残气容积(RV):(86.03±38.10)%;残总比(RV/TLC):(32.73±9.48)%;功能残气量(FRC):(84.91±28.08)%.27例患者基础肺功能下降的异常率:FVC:55.6%(15例);FEV1:44.4%(12例);FEV1/FVC:0%(0例);PEF:3.7 %(1例);DLCO:88.9%(24例);DLCO/VA:70.4%(19例).12例患者肺容积的异常率:TLC下降者占50%(6例);RV下降者占41.7%(5例),升高者占16.7%(2例);RV/TLC升高者占50%(6例);FRC下降者占33.3%(4例).10例进行BAL治疗的患者术后肺功能改善率:FVC:5.47%;FEV1:5.50%;DLCO:31.07%;DLCO/VA:20.35%.灌洗前后DLCO及DLCO/VA差异有统计学意义(t=-3.551,-3.159;P=0.006,0.012).结论 PAP的肺功能检查以肺限制性通气功能障碍及肺弥散功能障碍为常见,尤其为弥散功能障碍.PAP经BAL治疗后肺弥散功能有显著性改善.     

狼疮性肾炎患者肺功能损害特征及其相关因素分析

目的　探讨狼疮性肾炎患者肺功能损害的特征及其相关因素。方法　测定 40例狼疮性肾炎患者的肺容量、通气功能、小气道功能、弥散功能和血红蛋白、BUN及血压。结果　肺活量 (VC)、残气容积与肺总量之比值 (RV/TLC)、第一秒肺活量 (FEV1)、最大通气量 (MVV)、一氧化碳弥散量 (DLCO)、每升肺泡通气量之CO弥散量 (DLCO/VA)与对照组比较 ,差异有显著性 (P <0 .0 5 ) ,其中 30 %的患者呈现肺气肿现象 ,30 %的患者肺通气功能减低 ,小气道阻塞和可疑小气道阻塞者高达 6 0 % ,更有高达 85 %的患者弥散功能减退 ;相关因素分析表明 ,DLCO与TLC明显正相关关系 (r =0 .42 ,P <0 .0 5 )。结论　狼疮性肾炎患者肺功能损害以弥散功能减退为主 ,限制性通气障碍与阻塞性通气障碍并存 ,且以限制性通气障碍为主要发展趋势 ,与其他结缔组织疾病一样弥散功能障碍先于肺X线表现 ,但其呼吸困难症状几乎与弥散功能同步出现 ,则与其他结缔组织疾病有所不同     

老年慢性阻塞性肺疾病患者肺容量和弥散功能变化与疾病严重程度的关系

目的探讨老年慢性阻塞性肺疾病(COPD)患者肺容量和弥散功能变化与疾病严重程度的关系。方法老年COPD患者200例根据病情严重程度分成1级51例、2级61例、3级43例、4级45例,对比各组肺容量及弥散功能相关指标,分析患者各指标间的相关性。结果随着老年COPD患者疾病严重程度的加剧,其第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)、峰值呼气流量(PEF)、最大呼气中段流量(MMEF)及一氧化碳的弥散量(DLCO)水平逐渐降低,而残气容积(RV)(体描)、RV/肺总量(TLC)(体描)、△TLC及△RV水平逐渐升高,差异有统计学意义(P<0.05)。2~4级患者TLC(体描)水平明显高于1级患者,3~4级患者△RV/TLC水平明显高于1级及2级患者(P<0.05)。患者的△TLC、△RV及RV/TLC(体描)均分别与FEV1、FEV1/FVC、PEF、MMEF呈负相关,DLCO分别与FEV1、FEV1/FVC、PEF、MMEF呈正相关。结论老年COPD患者的肺容量及弥散功能的改变与其疾病的严重程度之间具有紧密的关系,随着疾病严重程度的加剧,其肺容量及其弥散功能均会受到影响。     

结节病患者肺功能与支气管肺泡灌洗液细胞学关系的研究

目的 探讨结节病患者不同影像分期之间肺功能指标、支气管肺泡灌洗液细胞学的改变以及两者的相关性.方法 回顾性调查71例结节病患者肺功能以及支气管肺泡灌洗液检查的资料.结果 在结节病患者不同影像分期之间肺功能指标用力肺活量(FVC)占预计值%、第1秒用力呼气容积(FEV1)占预计值%、肺总量(TLC)占预计值%以及肺一氧化...     

Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume

The volume dependence of single breath carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) was determined in 24 healthy subjects. The change in DLCO [fraction of DLCO measured at total lung capacity (TLC)] to change in alveolar volume [fraction of alveolar volume (VA) at TLC] closely fitted a simple linear regression and matched a theoretical model. As VA decreased, DLCO fell linearly and KCO increased as expected from the relation of DLCO to VA. The equations for adjustment of predicted DLCO and KCO for alveolar volume are: DLCO/DL COtlc = 0.58 + 0.42 VA/VAtlc, KCO/KCOtlc = 0.42 + 0.58/(VA/VAtlc). DLCO and KCO were evaluated in 2313 patients. Subgroups of patients with asthma, emphysema, extrapulmonary lung disease, interstitial lung disease and lung resection were identified. Unadjusted DLCO and KCO percent predicted values showed large differences and much variability, so can be misleading. As expected, KCO and DLCO percent predicted values adjusted for alveolar volume were nearly identical. Subgroups have characteristic patterns of VA and unadjusted and adjusted DLCO and KCO. Changes in DLCO and KCO with alveolar volume are relevant for accurate interpretation of diffusion in patients with low lung volumes. Adjusting predicted DLCO and KCO for alveolar volume provides a better assessment of lung function.     

2型糖尿病患者的肺功能损害及其相关因素分析

目的研究T2DM患者的肺功能损害及其影响因素。方法选取我院100例诊断为T2DM的患者及40名健康志愿者,检测肺功能及动脉血气进行对照研究,并以肺功能各项指标与FPG、胰岛素敏感性指数（ISI）、HbA1c、BMI和糖尿病病程等进行多因素线性回归分析。结果（1）T2DM组BMI明显高于对照组（P〈0．01）。（2）T2DM组肺总量（TLC）、用力肺活量（FVC）、1秒用力呼气量（FEV1）、用力呼出气量为50％肺活量的最大呼气中期流量（MMEF50）、用力呼出气量为25％肺活量的最大呼气中期流量（MMEF25）明显低于对照组（P〈0．01）。T2DM组一氧化碳弥散量（DLCO）、弥散指数（DLCO／VA）、动脉血氧分压（PaO2）和血氧饱和度（SaO2）低于对照组（P〈0．01）。（3）TLC、FVC、FEV1、MMEF50与FPG、2hPG、FC-P、2hC-P、HbA1c、BMI、ISI、病程无明显相关;但DL（如、DLCO／VA、MMEF25与FPG、2hPG、FC-P、2hC-P、HbA1c、BMI、病程呈显著负相关（P〈0．05或P〈0．01）,与ISI呈显著正相关（P〈0．05）。结论（1）T2DM患者肺功能损害主要表现为限制性通气功能障碍、小气道功能减退和弥散功能异常。（2）FPG、2hPG、FC-P、2hC-P、HbA1c、BMI、病程、ISI与T2DM小气道损害和肺弥散功能障碍密切相关。     

阿格列汀对经二甲双胍治疗的肥胖2型糖尿病患者肺功能的影响

目的观察阿格列汀对经二甲双胍治疗的肥胖2型糖尿病患者肺功能的影响,并评估该方案的有效性与安全性。方法选取肥胖的2型糖尿病患者100例(均为二甲双胍500 mg bid,po控制不佳),随机分为观察组(50例)和对照组(50例)。对照组给予二甲双胍(1000 mg bid,po),观察组为二甲双胍(500 mg bid,po)联合阿格列汀(25 mg qd,po),两组患者规范治疗24 w,比较两组患者治疗前后肺活量(VC)、用力肺活量(FVC)、肺总量(TCL)、一秒用力呼气流量(FEV1)、一秒率(FEV_1/FVC)、最大自主通气量(MVV)、最大呼气峰流速(PEF)、肺一氧化碳弥散量(DLCO)、肺单位体积一氧化碳弥散量(DLCO/VA)、外周血清超氧化物歧化酶(Superioxide dismutase,SOD)、活性氧类物质(Reactive oxygen species,ROS)、谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-Px)活性及其丙二醛(Malondialdehyde,MDA)浓度、体重指数、腰围、糖化血红蛋白(Hb A1c)、空腹血糖(FBG),餐后2 h血糖(2h PBG)的变化情况,并记录治疗过程中的不良反应。结果治疗后两组患者的VC、FVC、TLC、FEV1、FEV1/FVC、PEF、MVV、DLCO、DLCO/VA均高于治疗前(P0.05),治疗后对照组患者上述指标均低于观察组(P0.05)。治疗后,两组ROS、MDA、FBG、2h PBG、Hb A1c、体重指数、腰围,较治疗前均降低,有统计学差异(P0.05),治疗后观察组上述指标明显低于对照组,差异有统计学意义(P0.05);治疗后,SOD、GSH-Px活性较治疗前升高,差异有统计学意义(P0.05),治疗后观察组上述指标明显高于对照组,有统计学差异(P0.05),且治疗过程中两组的不良反应无统计学差异(P0.05)。结论阿格列汀联合二甲双胍可改善肥胖2型糖尿病患者的肺功能,改善外周血清氧化与抗氧化物质的失衡,同时能降低患者的体重指数、腰围等指标,且不增加低血糖风险,值得临床广泛推广。     

Respiratory function in children undergoing bone marrow transplantation.

We conducted a prospective study of respiratory function in children undergoing bone marrow transplantation (BMT) for onco-hematological disorders. Each child was evaluated before and 100 days after BMT. The investigations included clinical examination, chest X-ray, and pulmonary function tests (PFT) to determine: slow vital capacity (VC), functional residual capacity (FRC), total lung capacity (TLC), forced expiratory volume in 1 s (FEV1), carbon monoxide diffusing capacity (DLCO), ratio of residual volume (RV) to TLC, and FEV1/VC. The values obtained before and after BMT were compared to predicted values, and the post-BMT values were compared to the pre-BMT values (Student's t-test). From 1986 to 1995, 77 children underwent BMT, of whom 39 were available for testing. The pre-BMT VC (P = 0.0234) and DLCO (P < 0.0001) were lower and FRC higher (P < 0.0001) than predicted values. After BMT, the VC (P = 0.004), TLC (P = 0.044), and FEV1 (P = 0.012) were lower, and the RV/TLC ratio was higher (P = 0.043), compared with pre-BMT data. The observed respiratory abnormalities were not clinically relevant. The only identifiable risk factor for a decrease in lung function was age at BMT. This study shows that some lung dysfunction may be present before BMT and be further altered by BMT. This stresses the need for longitudinal respiratory monitoring and follow up to detect such dysfunctions and to insure an optimal treatment program for these children.     

Time-related decrease in diffusion capacity in HIV-infected patients with impaired immune function.

The purpose of this study was to investigate acute and time-related changes in lung function, i.e. forced expiratory volume in 1 second (FEV1), vital capacity (VC) and transfer factor (KCO) in HIV-infected patients with CD4 cell counts less than 400 x 10(6)/l. 66 males with no history of HIV-related pulmonary symptoms participated in a prospective lung function study for 9 months with 3-month intervals between examinations. 15/66 patients (23%) developed acute pulmonary symptoms, i.e. dyspnea (n = 12), cough (n = 13), fever greater than 38 degrees C (n = 13) and interstitial infiltrates on the X-ray (n = 9). Among the 51 asymptomatic patients, a significant time-related decrease in KCO (median decrease of 7%) was found, whereas no significant change in FEV1 or VC was observed during the study. Baseline KCO, i.e. KCO at entry, was found to be significantly higher in the asymptomatic patients (102% predicted (pred.) than in those patients who developed pneumonia (88% pred.). Development of pulmonary symptoms was both followed by a significant decrease in KCO (median decrease 17%), FEV1 and VC. We therefore conclude that HIV-infected patients with impaired immune function have in the absence of pulmonary symptoms a decrease in KCO. In case of pneumonia an acute decrease in both KCO, FEV1 and VC occurs.     

LUNG FUNCTION AND RESPIRATORY MUSCLE STRENGTH AFTER PROPRANOLOL IN THYROTOXICOSIS

Thirty-five thyrotoxic patients were assessed before treatment, after treatment with propranolol, and after antithyroid drugs. The first group of patients ( n = 17) performed the following tests at all three assessment points: forced expiratory volume in the first second (FEV,), vital capacity (VC), functional residual capacity (FRC), residual volume (RV), total lung capacity (TLC), maximal mid-expiratory flow rate (MMFR), diffusing capacity for carbon monoxide (DLCO), and maximum static inspiratory and expiratory mouth pressures (Plmax and PEmax). Arterial blood gas analysis was also performed for the first group of patients. No significant changes were seen either after propranolol or after antithyroid drugs in the FRC, RV, TLC, MMFR, DLCO, or blood gases. The remaining 18 patients, group 2, performed only the FEV₁, VC, Plmax, and PEmax tests at each assessment. The only index of respiratory function that improved significantly after propranolol was Plmax (from 46.5 ± 16.5 to 53.2 ± 22 cmH₂O, p < 0.01). This suggests that adrenergic excess may play a role in thyrotoxic inspiratory muscle weakness. After antithyroid drugs, Plmax, PEmax, FEV₁, and VC all increased significantly as expected. (Aust NZ J Med 1986; 16: 496–500.)     

Pulmonary function in patients with diabetes mellitus

BACKGROUND: Pulmonary complications of diabetes mellitus have been poorly characterized. Although some authors have reported normal pulmonary function, others found abnormalities in lung volumes, pulmonary mechanics, and diffusing capacity. SUBJECTS AND METHODS: We studied pulmonary function in a group of patients with diabetes using a combined cardiopulmonary exercise test. Twenty-seven patients with diabetes aged 48 +/- 13 years participated in the study. RESULTS: Overall, forced vital capacity, forced expiratory volume in 1 second, and forced expiratory flow, midexpiratory phase, were within the predicted values, but the residual volume/total lung capacity ratio was slightly elevated. Comparison by diabetes type showed nonsignificant differences in forced expiratory volume in 1 second and forced expiratory flow, midexpiratory phase. Residual volume/total lung capacity ratio was significantly elevated in type 1 patients compared with type 2. Carbon monoxide diffusion capacity (DLCO) was normal in both groups. There was no correlation between the results on pulmonary function test and duration of disease, presence of microangiopathy, or glycemic control. The DLCO was significantly lower in patients with microangiopathic changes, but not when DLCO was corrected for alveolar volume. On the cardiopulmonary exercise test, maximal workload, maximum oxygen uptake, and maximal heart rate were less than predicted, whereas anaerobic threshold and ventilatory reserve were normal. No significant differences were noted in diabetes type, and there was no correlation between parameters of cardiopulmonary exercise test and the other variables. CONCLUSION: Spirometric values are preserved in patients with diabetes mellitus, and there are no defects in diffusing capacity. Cardiovascular factors may account for impaired physical performance. There is no need for routine screening of pulmonary function among diabetic patients.     

肺泡蛋白沉着症患者的肺功能与胸部分辨率CT的相关性

目的 探讨PAP患者的肺功能与高分辨率CT定量测量指标之间的相关性.方法 对2004至2007年在广州医学院第一附属医院呼吸疾病研究所住院的17例PAP患者(男10例,女7例,年龄15～51岁)进行肺通气及弥散功能检查和高分辨率CT检查,分析肺功能指标与高分辨率CT定量指标之间的相关性.比较其中6例行全肺肺泡灌洗治疗前、后的肺功能和高分辨率CT定量指标的变化.采用SPSS 13.0软件进行数据处理,结果 以x±s表示.结果 PAP患者的肺功能检查结果 以限制性通气功能障碍和弥散功能下降为主,弥散功能下降更为显著,DLCO占预计值%为(46±22)%,异常率为94.1%.肺功能检查结果 与高分辨率CT定量检查结果 之间存在一定的相关性,其中平均肺密度与FVC、肺重量与FEV1、肺含气容积比与呼气峰流量、DL.CO、DLCO与肺泡通气量比值(DLCO/VA)等指标的改变差异有统计学意义,(r值分别为-0.469、-0.482、0.511、0.659、0.692,均P<0.05),在所有指标中以肺含气容积比与DLCO/VA关系最为密切.6例肺泡灌洗术治疗的患者术后肺功能和高分辨率CT定量测量指标有所改善.结论 PAP的肺功能和胸部高分辨率CT改变之间存在相关性.2项检查同时进行可作为PAP患者随访的重要参考指标.